Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Company Profile

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate is GT-02287, which is currently in...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 500 1556

Website: gaintherapeutics.com

Address:

4800 Montgomery Lane, Suite 220, Bethesda, United States

Jwelz90 Feb. 24 at 10:32 AM

$GANX

0 · Reply

rustinpeace Feb. 24 at 7:18 AM

$GANX part =1 How the SEE-Tx Algorithm Works (Step-by-Step) Starts with a 3D Protein Structure — Uses the published or modeled 3D structure of a target protein (e.g., an enzyme like GCase in PD or Gaucher disease). Molecular Dynamics Simulations — Runs physics-based simulations (molecular dynamics) on a supercomputer to probe the protein's surface and dynamics. Probes for Binding Hot Spots — Uses a range of organic solvent molecules (probes) as "test ligands" to scan the protein surface. It simulates how these probes interact at different sites. Calculates ΔG (Binding Free Energy Changes) — For each potential interaction site, the algorithm computes the change in binding free energy (ΔG) when a probe binds. This ΔG quantifies how favorable (negative ΔG = strong binding) or unfavorable the interaction is at an atomic level. Identifies Druggable Hot Spots — Sites with significant favorable ΔG changes (indicating strong, stable binding potential) are flagged as druggable binding hot spots.

1 · Reply

rustinpeace Feb. 24 at 7:12 AM

$GANX What makes Gain Therapeutics different? What Makes Gain Therapeutics' SEE-Tx Platform Unique? Gain Therapeutics' SEE-Tx patented algorithm provides quantitative predictions of druggable binding hot spots based on changes in binding free energy (ΔG). No other company has an algorithm like Gain Therapeutics that can quantify druggability of binding sites. from just a basic google search. i didnt know about the SEE-Tx algo. interesting

1 · Reply

rustinpeace Feb. 24 at 7:09 AM

$GANX https://public.com/stocks/ganx/forecast-price-target?wpsrc=Organic+Search&wpsn=www.google.com#:~:text=Gain%20Therapeutics%20(GANX)%20has%20been,0%25%20predict%20a%20Strong%20Sell.

0 · Reply

rustinpeace Feb. 24 at 3:47 AM

$GANX NIN Fiserv forum Milwaukee. 😈.

1 · Reply

zampy Feb. 24 at 1:52 AM

$GANX I dont believe we dont get anything from the fire side chat...inspite of that we are going higher this week and will cross over $2.35 this week.... MARCH MADNESS WELL OVER $3.X PLUS....LIKELY $4+

1 · Reply

microcapspeculator Feb. 24 at 12:06 AM

$GANX The moderator at Sachs is Jay Olson from Oppenheimer. In case someone wonders how close M. J. Fox Foundation is to Gain they cant get much closer than this picture. Im sure we will see Jay again at the fireside chat where Gene can tell us whatever he wants to share.

0 · Reply

zampy Feb. 23 at 11:41 PM

$GANX Please wish JWA a very Happy Birthday..... The best is yet to come....

0 · Reply

TommyGetty Feb. 23 at 11:27 PM

$GANX Dear bears, one thing to look for is that potential morning spike tomorrow am. otherwise blue skies. Im not margin called till 2.25 at this point so im still good.

1 · Reply

TommyGetty Feb. 23 at 11:21 PM

$GANX JEEESUZ, got back from lunch to check in on the close - just for eyes to start seeing blurred technicolor. WTF was that close all about? Not getting margin called anytime soon but something is definitely sus

1 · Reply

Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

Jan 7, 2026, 7:00 AM EST - 6 weeks ago

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Jan 6, 2026, 7:00 AM EST - 6 weeks ago

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

Dec 18, 2025, 4:05 PM EST - 2 months ago

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

Dec 18, 2025, 7:00 AM EST - 2 months ago

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease

Nov 20, 2025, 7:00 AM EST - 3 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

Nov 12, 2025, 7:00 AM EST - 3 months ago

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

Nov 7, 2025, 4:16 AM EST - 3 months ago

Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Gain Therapeutics to Present at Neuroscience 2025

Oct 16, 2025, 7:00 AM EDT - 4 months ago

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

Oct 6, 2025, 8:15 AM EDT - 5 months ago

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders®

Sep 23, 2025, 7:40 AM EDT - 5 months ago

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

Sep 18, 2025, 7:41 AM EDT - 5 months ago

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease

Sep 4, 2025, 8:00 AM EDT - 6 months ago

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

Aug 12, 2025, 7:00 AM EDT - 6 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

Jul 24, 2025, 8:53 AM EDT - 7 months ago

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

Jul 16, 2025, 9:03 AM EDT - 7 months ago

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

Jul 15, 2025, 4:36 PM EDT - 7 months ago

Gain Therapeutics Announces Proposed Public Offering

Jun 30, 2025, 4:05 PM EDT - 8 months ago

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

Jun 10, 2025, 8:00 AM EDT - 9 months ago

Gain Therapeutics to Participate in Upcoming Investor Conferences

May 29, 2025, 8:45 AM EDT - 9 months ago

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 14, 2025, 7:30 AM EDT - 10 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 12, 2025, 7:30 AM EDT - 10 months ago

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 1, 2025, 7:30 AM EDT - 10 months ago

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

Apr 30, 2025, 7:45 AM EDT - 10 months ago

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

Mar 28, 2025, 8:30 AM EDT - 11 months ago

Gain Therapeutics Announces Poster Presentation at AD/PD 2025

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

Mar 14, 2025, 7:45 AM EDT - 1 year ago

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

Mar 6, 2025, 7:55 AM EST - 1 year ago

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

Feb 6, 2025, 8:45 AM EST - 1 year ago

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

Feb 5, 2025, 8:30 AM EST - 1 year ago

Gain Therapeutics To Participate in Upcoming Investor Conferences

Dec 31, 2024, 12:23 PM EST - 1 year ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 1 year ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 1 year ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 1 year ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 1 year ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 1 year ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 1 year ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 13, 2024, 9:00 PM EDT - 1 year ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

May 30, 2024, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024, 6:15 PM EDT - 1 year ago

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

Jwelz90 Feb. 24 at 10:32 AM

$GANX

0 · Reply

rustinpeace Feb. 24 at 7:18 AM

1 · Reply

rustinpeace Feb. 24 at 7:12 AM

1 · Reply

rustinpeace Feb. 24 at 7:09 AM

$GANX https://public.com/stocks/ganx/forecast-price-target?wpsrc=Organic+Search&wpsn=www.google.com#:~:text=Gain%20Therapeutics%20(GANX)%20has%20been,0%25%20predict%20a%20Strong%20Sell.

0 · Reply

rustinpeace Feb. 24 at 3:47 AM

$GANX NIN Fiserv forum Milwaukee. 😈.

1 · Reply

zampy Feb. 24 at 1:52 AM

1 · Reply

microcapspeculator Feb. 24 at 12:06 AM

0 · Reply

zampy Feb. 23 at 11:41 PM

$GANX Please wish JWA a very Happy Birthday..... The best is yet to come....

0 · Reply

TommyGetty Feb. 23 at 11:27 PM

$GANX Dear bears, one thing to look for is that potential morning spike tomorrow am. otherwise blue skies. Im not margin called till 2.25 at this point so im still good.

1 · Reply

TommyGetty Feb. 23 at 11:21 PM

1 · Reply

rustinpeace Feb. 23 at 10:59 PM

$GANX we’re pushing the bullish to extremely bullish on sentiment Meter. Might gain more watchers /retail investors at some point as we should show up on the bullish list. Def couldn’t hurt.

1 · Reply

rustinpeace Feb. 23 at 10:55 PM

$GANX 2.10 AH price.

0 · Reply

Jwelz90 Feb. 23 at 10:09 PM

$GANX Beautiful break, test/hold, continue of the hourly 200ema today. Daily 50ema and 200ema at 2.19 and 2.21. Would imagine those wont be near as easy, especially this hot as it is currently on shorter timeframes. But like earlier, will gladly watch it blow through instead and keep going lol.

0 · Reply

Cmoneyyyyy11 Feb. 23 at 9:40 PM

$GANX tommy does your dumb ass have any more inside plays??? might want to get in with ya on the next one

1 · Reply

IwM Feb. 23 at 9:16 PM

$GANX marked #safe from Anthropic AI disruption One thing about novel science… is that it is patented/protected We happen to have our own AI discovery tool 💁🏼‍♀️

0 · Reply

RealMcCoin Feb. 23 at 9:02 PM

$GANX Never been so happy to see a stock back over $2. I think the word is out my friends!

2 · Reply

MQuick Feb. 23 at 8:59 PM

$GANX certainly feels like something is going on

0 · Reply

mwb1 Feb. 23 at 8:58 PM

$GANX

0 · Reply

MQuick Feb. 23 at 8:37 PM

$GANX pre clinical assets have sold for 5-15x our current cap

0 · Reply

MQuick Feb. 23 at 8:28 PM

$GANX have to imagine that by now BP has their arms fully wrapped around this and understand what we have. Lets wait and see!

1 · Reply

Mstngman99 Feb. 23 at 8:08 PM

$GANX Feeling bad for the unnamed bear in here. Sometimes a stuff animal can give comfort when you feel like it’s you versus the world. Life isn’t always fair…

1 · Reply

zampy Feb. 23 at 8:07 PM

$GANX Shutout to Tommy...You are a genius!!!! Take your ball and go home.. We are trying to help people with Parkinson's and we will. It shows what a true POS you are.. MARCH MADNESS $2.X.35 THIS WEEK

0 · Reply

Market Cap	74.62M
Revenue (ttm)	0.00
Net Income (ttm)	-20.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.07

Volume	592,800
Avg Vol	1,301,844
Day's Range	N/A - N/A
Shares Out	38.46M
Stochastic %K	97%
Beta	0.05
Analysts	Strong Sell
Price Target	$7.60